Gencurix Inc. Logo

Gencurix Inc.

Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.

229000 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 243 지하이시티 15층, 구로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gencurix Inc. is a molecular diagnostics company specializing in the development and commercialization of innovative solutions for oncology. The company leverages core technologies such as liquid biopsy and digital PCR (dPCR) to create precise and reliable tests for cancer detection, prognosis, and treatment selection. Its key products include GenesWell BCT, a multigene test for predicting prognosis in early-stage breast cancer patients, and the GenesWell ddEGFR Mutation Test, a dPCR-based companion diagnostic for targeted anticancer therapies. Gencurix also develops the Droplex platform for early cancer detection by analyzing biomarkers from blood samples. The company aims to advance precision medicine and improve patient outcomes through its portfolio of diagnostic tests and services.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Gencurix Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-28 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 9.7 KB
2025-08-28 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.6 KB
2025-08-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-08-13 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 16.6 KB
2025-08-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 56.4 KB
2025-08-13 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 53.0 KB

Automate Your Workflow. Get a real-time feed of all Gencurix Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Gencurix Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan 4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland SANN
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan 4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark SCOL
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea 298060
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea 096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan 4548
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea 018680

Talk to a Data Expert

Have a question? We'll get back to you promptly.